ATE333467T1 - Peptide zum einsatz in der behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern - Google Patents

Peptide zum einsatz in der behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern

Info

Publication number
ATE333467T1
ATE333467T1 AT02779063T AT02779063T ATE333467T1 AT E333467 T1 ATE333467 T1 AT E333467T1 AT 02779063 T AT02779063 T AT 02779063T AT 02779063 T AT02779063 T AT 02779063T AT E333467 T1 ATE333467 T1 AT E333467T1
Authority
AT
Austria
Prior art keywords
peptides
removal
cells
tumors
destroy
Prior art date
Application number
AT02779063T
Other languages
English (en)
Inventor
Paul Averback
Jack Gemmell
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Application granted granted Critical
Publication of ATE333467T1 publication Critical patent/ATE333467T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
AT02779063T 2001-11-16 2002-11-18 Peptide zum einsatz in der behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern ATE333467T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33147701P 2001-11-16 2001-11-16

Publications (1)

Publication Number Publication Date
ATE333467T1 true ATE333467T1 (de) 2006-08-15

Family

ID=23294135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779063T ATE333467T1 (de) 2001-11-16 2002-11-18 Peptide zum einsatz in der behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern

Country Status (22)

Country Link
US (5) US7317077B2 (de)
EP (1) EP1442058B1 (de)
JP (2) JP4717349B2 (de)
KR (4) KR20120123573A (de)
CN (1) CN100509846C (de)
AT (1) ATE333467T1 (de)
AU (1) AU2002342463B2 (de)
BR (1) BRPI0213786B8 (de)
CA (1) CA2467053C (de)
CY (1) CY1107578T1 (de)
DE (1) DE60213274T2 (de)
DK (1) DK1442058T3 (de)
EA (1) EA007203B1 (de)
ES (1) ES2269775T3 (de)
IL (2) IL161591A0 (de)
MX (1) MXPA04004489A (de)
NO (1) NO332842B1 (de)
NZ (1) NZ532721A (de)
PL (1) PL207591B1 (de)
PT (1) PT1442058E (de)
WO (1) WO2003044053A2 (de)
ZA (1) ZA200403624B (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE202004021947U1 (de) 2003-09-12 2013-05-13 Vessix Vascular, Inc. Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material
US20090232866A1 (en) * 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
US20050226883A1 (en) * 2004-02-06 2005-10-13 Paul Averback Humanized antibody
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8920414B2 (en) 2004-09-10 2014-12-30 Vessix Vascular, Inc. Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
CN100427502C (zh) * 2005-06-09 2008-10-22 南京大学 抗肿瘤寡肽及其制备方法和应用
CA2628271A1 (en) * 2005-11-02 2007-05-10 Sure International Ventures B.V. Compositions and methods for cell killing
CN101389760A (zh) 2006-02-28 2009-03-18 尼莫克斯股份有限公司 有效治疗肿瘤或其他需要除去或破坏细胞的病症的肽
CA2643239A1 (en) * 2006-03-10 2007-09-20 Nymox Corporation Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ES2407329T3 (es) 2006-10-18 2013-06-12 Vessix Vascular, Inc. Sistema para inducir efectos de temperatura deseables sobre un tejido corporal
AU2007310986B2 (en) 2006-10-18 2013-07-04 Boston Scientific Scimed, Inc. Inducing desirable temperature effects on body tissue
AU2009314133B2 (en) 2008-11-17 2015-12-10 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US8703138B2 (en) 2009-04-13 2014-04-22 The Feinstein Institute For Medical Research Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)
CA2795229A1 (en) 2010-04-09 2011-10-13 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
WO2013013156A2 (en) 2011-07-20 2013-01-24 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
JP6106669B2 (ja) 2011-07-22 2017-04-05 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． ヘリカル・ガイド内に配置可能な神経調節要素を有する神経調節システム
WO2013055826A1 (en) 2011-10-10 2013-04-18 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
WO2013058962A1 (en) 2011-10-18 2013-04-25 Boston Scientific Scimed, Inc. Deflectable medical devices
EP2768568B1 (de) 2011-10-18 2020-05-06 Boston Scientific Scimed, Inc. Ballonkatheter mit integrierter vernetzung
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
EP2779929A1 (de) 2011-11-15 2014-09-24 Boston Scientific Scimed, Inc. Vorrichtung und verfahren zur überwachung von nierennervenmodulation
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9037259B2 (en) 2011-12-23 2015-05-19 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
CN104135958B (zh) 2011-12-28 2017-05-03 波士顿科学西美德公司 用有聚合物消融元件的新消融导管调变神经的装置和方法
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
WO2014032016A1 (en) 2012-08-24 2014-02-27 Boston Scientific Scimed, Inc. Intravascular catheter with a balloon comprising separate microporous regions
EP2895095A2 (de) 2012-09-17 2015-07-22 Boston Scientific Scimed, Inc. Selbstpositionierendes elektrodensystem und verfahren für renale nervenmodulation
WO2014047454A2 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
CN104869930B (zh) 2012-10-10 2020-12-25 波士顿科学国际有限公司 肾神经调制装置和方法
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
WO2014143571A1 (en) 2013-03-11 2014-09-18 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
EP2967734B1 (de) 2013-03-15 2019-05-15 Boston Scientific Scimed, Inc. Verfahren und vorrichtungen zur gewebeneumodellierung in oder neben einem körperdurchgang
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
JP6139772B2 (ja) 2013-03-15 2017-05-31 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 電極パッドと共に使用するための制御ユニットおよび漏電を推定するための方法
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
WO2014205388A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
JP6204579B2 (ja) 2013-07-01 2017-09-27 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 腎神経アブレーション用医療器具
WO2015006480A1 (en) 2013-07-11 2015-01-15 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
EP3019106A1 (de) 2013-07-11 2016-05-18 Boston Scientific Scimed, Inc. Medizinische vorrichtung mit dehnbaren elektrodenanordnungen
EP3049007B1 (de) 2013-07-19 2019-06-12 Boston Scientific Scimed, Inc. Nierendenervierungsballon mit spiralförmiger bipolarer elektrode
WO2015013301A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10722300B2 (en) 2013-08-22 2020-07-28 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
WO2015035047A1 (en) 2013-09-04 2015-03-12 Boston Scientific Scimed, Inc. Radio frequency (rf) balloon catheter having flushing and cooling capability
EP3043733A1 (de) 2013-09-13 2016-07-20 Boston Scientific Scimed, Inc. Ablationsballon mit aufgedampfter deckschicht
EP3049438B1 (de) 2013-09-24 2018-07-25 The Feinstein Institute for Medical Research Peptide zur hemmung von kälteinduzierbarer rns-bindender proteinaktivität
CN105592778B (zh) 2013-10-14 2019-07-23 波士顿科学医学有限公司 高分辨率心脏标测电极阵列导管
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
JP6259098B2 (ja) 2013-10-15 2018-01-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 医療デバイスおよび同医療デバイスを製造する方法
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
JP6259099B2 (ja) 2013-10-18 2018-01-10 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 可撓性を備える導電性ワイヤを備えるバルーン・カテーテル、並びに関連する使用および製造方法
CN105658163B (zh) 2013-10-25 2020-08-18 波士顿科学国际有限公司 去神经柔性电路中的嵌入式热电偶
US11202671B2 (en) 2014-01-06 2021-12-21 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US10078207B2 (en) 2015-03-18 2018-09-18 Endochoice, Inc. Systems and methods for image magnification using relative movement between an image sensor and a lens assembly
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
WO2017000060A1 (en) * 2015-06-29 2017-01-05 The University Of British Columbia Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) * 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594863A (en) * 1897-12-07 Otto p
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
ES2094733T3 (es) 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
DK1564293T3 (da) 1993-04-20 2009-01-12 Gen Hospital Corp Nervetrådproteingenekspression og detektion af Alzheimers sygdom
FR2757486B1 (fr) 1996-12-24 1999-03-26 Sanofi Sa Receptacle de conditionnement de deux produits pouvant s'ecouler et maintenus separes avant d'etre melanges pour utilisation
NZ337445A (en) 1997-02-26 2000-12-22 Gen Hospital Corp Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
US6238667B1 (en) * 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
WO2000000157A2 (en) * 1998-06-26 2000-01-06 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
AU2185199A (en) * 1998-09-30 2000-04-17 Yoko Aida Apoptosis inducers
CA2353797A1 (en) * 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
EA200100770A1 (ru) * 1999-01-11 2002-02-28 Леадд Б.В. Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний
CA2364630A1 (en) 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 50 human secreted proteins
WO2000058495A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 45 human secreted proteins
CA2365223A1 (en) 1999-03-19 2000-09-28 Craig A. Rosen 46 human secreted proteins
CA2368281A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 50 human secreted proteins
EP1171462A2 (de) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 menschliche ausscheidungsproteine
MXPA02004934A (es) 1999-11-16 2004-08-12 Unilever Nv Composiciones cosmeticas conteniendo extracto de anis y retinoides.
AU1940001A (en) 1999-11-30 2001-06-12 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
US20020127671A1 (en) 2000-06-26 2002-09-12 Curtis Rory A.J. 52927, a novel human calcium channel and uses thereof
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
KR20040008177A (ko) * 2001-05-16 2004-01-28 니목스 코포레이션 신경 사 단백질 세그먼트를 사용하여 세포 사멸을억제하는 방법
KR100945383B1 (ko) 2001-05-25 2010-03-05 니목스 코포레이션 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
ES2281529T3 (es) * 2001-07-19 2007-10-01 Nymox Corporation Peptidos eficaces en el tratamiento de tumores y otras afecciones que requieren la eliminacion o destruccion de celulas.
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Also Published As

Publication number Publication date
IL161591A0 (en) 2004-09-27
CA2467053C (en) 2013-05-07
DE60213274D1 (de) 2006-08-31
JP2011135876A (ja) 2011-07-14
ES2269775T3 (es) 2007-04-01
US7317077B2 (en) 2008-01-08
PT1442058E (pt) 2006-12-29
PL370891A1 (en) 2005-05-30
CN100509846C (zh) 2009-07-08
DE60213274T2 (de) 2007-10-31
KR20140044399A (ko) 2014-04-14
IL161591A (en) 2010-02-17
JP2005521383A (ja) 2005-07-21
EA200400632A1 (ru) 2004-10-28
NZ532721A (en) 2007-05-31
AU2002342463A1 (en) 2003-06-10
NO20041844L (no) 2004-07-06
KR20110003552A (ko) 2011-01-12
WO2003044053A3 (en) 2003-12-11
WO2003044053A2 (en) 2003-05-30
BR0213786A (pt) 2004-11-09
US8293703B2 (en) 2012-10-23
US7745572B2 (en) 2010-06-29
US20030166569A1 (en) 2003-09-04
NO332842B1 (no) 2013-01-21
US8569446B2 (en) 2013-10-29
CN1589279A (zh) 2005-03-02
BRPI0213786B8 (pt) 2021-05-25
KR101375026B1 (ko) 2014-03-17
EP1442058B1 (de) 2006-07-19
PL207591B1 (pl) 2011-01-31
CY1107578T1 (el) 2013-03-13
ZA200403624B (en) 2005-12-28
JP5357196B2 (ja) 2013-12-04
JP4717349B2 (ja) 2011-07-06
KR20050044471A (ko) 2005-05-12
CA2467053A1 (en) 2003-05-30
DK1442058T3 (da) 2006-12-04
KR20120123573A (ko) 2012-11-08
US20130040900A1 (en) 2013-02-14
BRPI0213786B1 (pt) 2019-01-02
MXPA04004489A (es) 2004-11-29
US20090286742A1 (en) 2009-11-19
US7408021B2 (en) 2008-08-05
AU2002342463B2 (en) 2008-09-04
EA007203B1 (ru) 2006-08-25
US20050032704A1 (en) 2005-02-10
US20090022743A1 (en) 2009-01-22
EP1442058A2 (de) 2004-08-04

Similar Documents

Publication Publication Date Title
DE60213274D1 (de) Peptide zum einsatz in der behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
DE60217507D1 (de) Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
DE69836822D1 (de) Verfahren zur Behandlung von Kapseln und trockenen gepulverten pharmazeutischen Formulierungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE530560T1 (de) Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
DE60116467D1 (de) Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
EP1714979A3 (de) Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern
DE69816634D1 (de) Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
EP1847550A3 (de) Peptide zur effektiven Behandlung von Tumoren und anderen Bedingungen, die Zellentfernung oder- zerstörung erfordern
PT1450834E (pt) Absolutos de bolbos de allium sativum e utilizacoes terapeuticas ou cosmeticas
RU98123495A (ru) Способ лечения рака путем химического выключения "взбесившейся" (crazy) хромосомы

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1442058

Country of ref document: EP